Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma Journal Article
| Authors: | Lorenc, R.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Saldia, A.; Luna De Abia, A.; De Lapuerta, M. C.; Tomas, A. A.; Cassanello, G.; Leslie, L. A.; Rejeski, K.; Lin, R. J.; Scordo, M.; Shah, G. L.; Palomba, M. L.; Salles, G.; Park, J.; Giralt, S. A.; Perales, M. A.; Ip, A.; Dahi, P. B. |
| Article Title: | Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma |
| Abstract: | Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin lymphomas (B-NHL). With the remarkable success in improving survival, understanding the late effects of CAR T cell therapy is becoming more relevant. The aim of this study is to determine the incidence of subsequent malignancies in adult patients with B-NHL. We retrospectively studied 355 patients from 2 different medical centers treated with four different CAR T cell products from 2016 to 2022. The overall cumulative incidence for subsequent malignancies at 36 months was 14% (95% CI: 9.2%, 19%). Subsequent malignancies were grouped into 3 primary categories: solid tumor, hematologic malignancy, and dermatologic malignancy with cumulative incidences at 36 months of 6.1% (95% CI: 3.1%-10%), 4.5% (95% CI: 2.1%-8.1%) and 4.2% (95% CI: 2.1%-7.5%) respectively. Notably, no cases of T cell malignancies were observed. In univariable analysis, increasing age was associated with higher risk for subsequent malignancy. While the overall benefits of CAR T products continue to outweigh their potential risks, more studies and longer follow ups are needed to further demonstrate the risks, patterns, and molecular pathways that lead to the development of subsequent malignancies. © 2024 The American Society for Transplantation and Cellular Therapy |
| Keywords: | adult; cancer survival; controlled study; treatment outcome; treatment response; aged; major clinical study; overall survival; cancer risk; risk benefit analysis; solid tumor; follow up; melanoma; progression free survival; mantle cell lymphoma; basal cell carcinoma; skin cancer; autologous stem cell transplantation; hematopoietic stem cell transplantation; retrospective study; bladder cancer; late effects; cause of death; b cell lymphoma; hematologic malignancy; myelodysplastic syndrome; lung adenocarcinoma; karnofsky performance status; allogeneic hematopoietic stem cell transplantation; aging; prostate adenocarcinoma; transitional cell carcinoma; thyroid papillary carcinoma; follicular lymphoma; cd19 antigen; non-hodgkin lymphoma; sebaceous carcinoma; gastrointestinal cancer; non small cell lung cancer; cumulative incidence; central nervous system lymphoma; overall response rate; diffuse large b cell lymphoma; appendix carcinoma; primary cutaneous diffuse large b cell lymphoma leg type; human; male; female; article; squamous cell lung carcinoma; breast ductal carcinoma; tisagenlecleucel t; squamous cell skin carcinoma; chimeric antigen receptor t-cell immunotherapy; axicabtagene ciloleucel; lisocabtagene maraleucel; high grade b cell lymphoma; brexucabtagene autoleucel; neoplasms by histologic type; chimeric antigen receptor (car) t-cells; subsequent malignancy; t cell malignancy; epstein-barr virus-positive diffuse large b cell lymphoma; intravascularl low grade b cell lymphoma; primary diffuse large b cell lymphoma of the central nervous system; primary mediastinal low grade b cell lymphoma; t cell/histiocyte-rich large b cell lymphoma |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 30 |
| Issue: | 10 |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | 990 |
| End Page: | 1000 |
| Language: | English |
| DOI: | 10.1016/j.jtct.2024.06.027 |
| PUBMED: | 38972512 |
| PROVIDER: | scopus |
| PMCID: | PMC11427145 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Parastoo Dahi -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work